# US 2026/0283962 A1 · Pharmaceutical composition and method for enhancing solubility of poorly soluble active pharmaceutical ingredients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0283962 A1
- Document ID: US20260283962A1
- Status: Published application
- Kind: A1
- Application number: 18/881,106
- Filed: 2023-07-03
- Published: 2026-09-24
- Earliest claimed: 2022-07-06
- Assignees: Merck Patent GmbH
- Applicants: Merck Patent GmbH
- Inventors: Thomas KIPPING; Jonas LINDH; Julian QUODBACH
- Web page: https://patentgrep.com/patent/US20260283962A1

## CPC

- A61K 9/2095: {Tabletting processes}
- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure generally relates to the use of poloxamer in additive manufacturing technologies and techniques. More specifically, the present disclosure relates to the use of poloxamer in a selective laser sintering (SLS) method to additively manufacture an object, in particular a pharmaceutical dosage form. Also described is a process for selective laser sintering a sinter powder to form a pharmaceutical dosage form, in which the sinter powder includes at least one active pharmaceutical ingredient and at least one poloxamer with a melting point of 20° C. or higher.

## Claims

### Claim 1

A process for selective laser sintering of sinter powder to form a pharmaceutical dosage form, comprising sintering a sinter powder comprising at least one active pharmaceutical ingredient and at least one poloxamer with a melting point of 20° C. or higher.

### Claim 2 (depends on 1)

The process according to claim 1 wherein the melting point of the at least one poloxamer is between 40° C. and 60° C.

### Claim 3 (depends on 1)

The process according to claim 1, wherein the average molecular weight of the at least one poloxamer is 3000 Da or higher.

### Claim 4 (depends on 1)

The process according to claim 1, wherein the at least one poloxamer has a weight percentage of ethylene oxide chains between 50% and 90%.

### Claim 5 (depends on 1)

The process according to claim 1, wherein the at least one poloxamer is poloxamer P188 or P407.

### Claim 6 (depends on 1)

The process according to claim 1, wherein the sinter powder further comprises at least one light-absorbing material.

### Claim 7

A process for producing a pharmaceutical dosage form by selective laser sintering of sinter powder, comprising:
(a) providing a sinter powder comprising at least one active pharmaceutical ingredient and at least one poloxamer with a melting point of 20° C. or higher, and
(b) operating a selective laser sintering apparatus that selectively fuses layers of the sinter powder to produce the pharmaceutical dosage form.

### Claim 8 (depends on 7)

The process according to claim 7, wherein the pharmaceutical dosage is an amorphous solid dispersion of the at least one active pharmaceutical ingredient in the at least one poloxamer.

### Claim 9 (depends on 7)

The process according to claim 7, wherein the at least one poloxamer is poloxamer P188 or P407.

### Claim 10 (depends on 7)

The process according to claim 7, wherein the process temperatures are below the melting point of the at least one poloxamer.

### Claim 11 (depends on 7)

The process according to claim 7, wherein the particle size of the sinter powder has a D50 of 200 μm or lower.

### Claim 12 (depends on 7)

The process according to claim 7, wherein the sinter powder further comprises at least one light-absorbing material.

### Claim 13

A sinter powder for selective laser sintering, comprising at least one active pharmaceutical ingredient and at least one poloxamer having a melting point of 20° C. or higher.

### Claim 14 (depends on 13)

A sinter powder according to claim 13, further comprising at least one light-absorbing material.

### Claim 15 (depends on 7)

A pharmaceutical dosage form obtainable by a process according to claim 7.
